# Inflammation and Co-Infections in D²EFT

> **NCT04183738** · PHASE4 · WITHDRAWN · sponsor: **Kirby Institute**

## Conditions studied

- HIV-infection/Aids
- Human Herpesvirus 4 Infections
- Cytomegalovirus Infections
- Human Herpesvirus 8 Infection
- Human Papilloma Virus

## Interventions

- **DRUG:** NRTIs
- **DRUG:** Darunavir
- **DRUG:** Ritonavir
- **DRUG:** Dolutegravir

## Key facts

- **NCT ID:** NCT04183738
- **Lead sponsor:** Kirby Institute
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2021-02-01
- **Primary completion:** 2022-12-19
- **Final completion:** 2022-12-19
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** In the context of COVID-19 pandemic.
- **Last updated:** 2020-11-10

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04183738

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04183738, "Inflammation and Co-Infections in D²EFT". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT04183738. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*